" if any have yet been able to cross the brain blood barrier."
"Roche has claimed the latest phase 2 readout for its multiple sclerosis (MS) drug backs up the BTK inhibitor’s "best in disease" potential by achieving the "holy grail" in biopharma: crossing the blood-brain barrier."
Not relevant to what PAB are doing but looks like they are catching up. Link to article below -
Roche BTK inhibitor may show 'holy grail' of brain penetration (fiercebiotech.com)
- Forums
- ASX - By Stock
- PAB
- Ann: Appendix 4E and 2023 Annual Report
Ann: Appendix 4E and 2023 Annual Report, page-22
Featured News
Add PAB (ASX) to my watchlist
|
|||||
Last
0.7¢ |
Change
0.000(0.00%) |
Mkt cap ! $13.37M |
Open | High | Low | Value | Volume |
0.7¢ | 0.7¢ | 0.7¢ | $952 | 136.1K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
20 | 6215055 | 0.6¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
0.7¢ | 1726390 | 6 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
20 | 6215055 | 0.006 |
21 | 8280275 | 0.005 |
9 | 4927451 | 0.004 |
8 | 6400016 | 0.003 |
1 | 2520000 | 0.002 |
Price($) | Vol. | No. |
---|---|---|
0.007 | 1726390 | 6 |
0.008 | 2000000 | 2 |
0.009 | 1766604 | 3 |
0.010 | 1412000 | 3 |
0.011 | 1080000 | 2 |
Last trade - 10.09am 23/07/2024 (20 minute delay) ? |
Featured News
PAB (ASX) Chart |